.NET Authors: Lori MacVittie, Yeshim Deniz, Ivan Antsipau, Liz McMillan, Michael Bushong

News Feed Item

Hansen Medical Reports Full Year 2012 and Fourth Quarter Results

Record Annual Procedures and Catheter Sales; Six Consecutive Quarters of Procedure Growth Through Q4; Over 10,000 Patients Have Now Been Treated With Intravascular Robotics; Shipped Three Robotic Systems in Q4 and Three additional Robotic Systems in Febru

MOUNTAIN VIEW, CA -- (Marketwire) -- 02/27/13 -- Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today reported recent business highlights and financial results for the full year and fourth quarter ended December 31, 2012.

Full Year 2012 Summary and Recent Business Highlights

  • Full Year 2012 Results:
    • Shipped 12 robotic catheter systems: 6 Magellan™ Robotic Systems (4 U.S. and 2 internationally) and 6 Sensei® X Robotic Catheter Systems (3 U.S. and 3 internationally)
      • 3 of the shipped Magellan Robotic Systems and one of the shipped Sensei Robotic Systems were shipped under the company's commercial evaluation program
      • Shipped a total of 122 robotic systems worldwide since first commercial launch

    • Recognized revenue on 13 robotic systems (5 U.S. and 8 internationally)
      • 8 of the systems recognized as revenue were shipped in 2012 and 5 were shipped in previous years

    • We estimate a record 2,688 procedures performed, up 8% year over year

    • Sold a record 2,807 catheters, up 1% year over year

    • Generated revenue of $17.6 million, down 20% compared to 2011. 2011 revenue was higher than 2012 primarily due to the inclusion of 12 systems in 2011 revenue which had been shipped in 2010 and prior, compared to only 5 systems in 2012 revenue which had been shipped in previous years.

  • Shipped three additional Magellan Robotic Systems in February of 2013 to hospitals in Europe under the company's commercial evaluation program; the commercial evaluation program allows certain strategic accounts to install and utilize Hansen Medical robotic systems for a trial period while the purchase opportunity is being evaluated by the hospital

  • New Products:
    • Received U.S. regulatory clearance and launched our Magellan Robotic System including catheters and related accessories for peripheral vascular interventions
      • First Magellan System sold and clinical cases performed in the U.S.
      • Artisan® Extend Control Catheter cleared in the US and Europe, to improve clinical workflow and reduce manufacturing costs
      • Sensei X 4.1 software upgrade cleared in the US and Europe which provides enhanced visualization and clinical utility through improved third party product integration

  • Growing body of clinical data and physician presentations demonstrating clinical value of intravascular robotics
    • More than 10,000 patients have now been treated with Hansen Medical intravascular robotics
    • Four live cases successfully performed with Magellan Robotic System by Dr. Barry Katzen, founder and Medical Director of the Baptist Cardiac & Vascular Institute (Baptist Hospital of Miami), at Transcatheter Cardiovascular Therapeutics (TCT) conference and 25th Annual International Symposium on Endovascular Therapy (ISET)

  • Operational Excellence:
    • Lowered product costs through improved design, and productivity gains through lean manufacturing initiatives
    • Reduced operating expenses $11.9 million, or 22%, compared to 2011, excluding the $10.5 million impact of funded R&D credits received in 2011, as the company drove efficiencies across the organization and even though it added resources to commercial operations

  • Capital Raising Activities: Received $30 million from Intuitive Surgical (NASDAQ: ISRG) in the fourth quarter through a $20 million fee for an expanded license agreement and a $10 million private placement of Hansen Medical common stock at a 5% premium, with an 18 month lock-up

  • Expanded our broad and deep intellectual property portfolio for medical robotics through the issuance of 15 additional U.S. patents in 2012

  • Strengthened Leadership Team: Created new positions of Chief Operating Officer and Senior Vice President, Global Sales, and appointed new Vice President to oversee Global Marketing and Business Development initiatives, all intended to build further operational and commercial expertise

  • Board of Director Changes: Appointed four new directors in 2012, recruited to bring additional industry, operational and commercial expertise to the Board

Fourth Quarter 2012 Financial Summary

  • Shipped three systems (1 Magellan system and 2 Sensei systems)
    • Of the three systems shipped in the fourth quarter, one Sensei system was part of our commercial evaluation program

  • Generated revenue of $4.3 million in the fourth quarter, down 30% year over year
    • Recognized revenue on 2 systems during the fourth quarter, including 1 Magellan system and 1 Sensei system
    • Sold a record 840 catheters in the fourth quarter, up 22% sequentially and 18% year over year

  • We estimate physicians performed a record 755 Hansen robotic procedures in the fourth quarter, up 15% sequentially and 19% year over year. This is the sixth consecutive quarter of estimated procedure growth.

  • Held cash, cash equivalents and short-term investments of $41.2 million at December 31, 2012, representing a quarterly cash gain of $19.5 million. The current quarter cash position was positively impacted by the receipt of $30 million from the expanded licensing agreement with and stock purchase by Intuitive Surgical, and negatively impacted by a $620,000 negative valuation adjustment of a short-term investment. Excluding these items, cash burn in the quarter would have been $9.9 million.

"2012 was a strong year for Hansen Medical, as we achieved one of the most significant milestones in the Company's history with the receipt of FDA clearance for our Magellan Robotic System, and the subsequent first system sale and clinical cases in the U.S.," said Bruce Barclay, Hansen Medical's President and Chief Executive Officer. "The Magellan System has the potential to be a significant growth driver for our business and to transform the way endovascular procedures are performed. Since commencing the initial U.S. launch of the Magellan System in June, we have generated a large and growing pipeline of clinical interest in our robotic technology through live case demonstrations and multiple presentations by leading physicians at prominent industry conferences. While the difficult macroeconomic environment has caused hospitals to prolong their evaluation period for new technologies, we anticipate that at least nine Magellan Systems will be installed in hospitals by the end of the first quarter, and I expect that the adoption of our technology will grow as physicians generate additional clinical data."

"I am also pleased to announce that we have delivered annual records for catheters sold and procedures performed by our customers, as well as six consecutive quarters of procedure growth. The strong procedure rates and catheter sales seen in recent quarters, driven primarily by our base electrophysiology business and to a lesser extent by the introduction of our Magellan System, are indicative of the significant value we believe physicians and hospitals can, and are, deriving from our intravascular robotic systems. More than 10,000 patients have now received the benefits of intravascular robotics from Hansen Medical, and this is a testament to the innovation and hard work of all of our employees."

Mr. Barclay continued, "Finally, our expanded licensing agreement with Intuitive Surgical is a validation of our technology from the global leader in medical robotics and has further bolstered our balance sheet and provided us with capital to continue to support the initial global launch of the Magellan System."

2012 Fourth Quarter Financial Results

Total revenue for the fourth quarter ended December 31, 2012 was $4.3 million compared to revenue of $6.2 million in the same period in 2011. During the fourth quarter, the Company shipped 3 systems (2 Sensei systems and 1 Magellan system) and recognized revenue on 2 systems (1 Magellan system and 1 Sensei system), as well as shipment of a record 840 catheters. Catheter sales were up 22% compared to the fourth quarter of 2011 and up 18% sequentially. Further, an estimated record 755 Hansen robotic procedures were performed in the period, an increase of 19% compared to the same quarter of the prior year, and up 15% sequentially.

Cost of revenues for the fourth quarter was $3.5 million. As a result, gross profit for the quarter was $868,000 or 20% of revenue, compared to gross profit of $1.6 million, or 27% of revenue for the same period in 2011. The decrease in gross profit in the current quarter is primarily the result of fewer system sales, partially offset by continued improvement in catheter and service margins.

Research and development expenses for the fourth quarter were $3.5 million, compared to $1.9 million for the same period in 2011. The 2011 amount included $3.7 million of funded research and development credits (recorded as a reduction of expense) from our now completed work under our joint development agreement with Philips. Excluding these research and development credits in the fourth quarter of 2011, prior year research and development expenses were higher primarily due to additional development costs associated with the Company's Magellan System and higher employee related costs.

Selling, general and administrative expenses for the fourth quarter were $6.9 million, compared to $8.6 million for the same period of 2011. The net decrease in the current quarter is primarily due to lower legal fees and stock based compensation.

Net income for the fourth quarter was $9.6 million, or $0.15 per share, based on average shares outstanding of 65.3 million. This compares with a net loss for the fourth quarter of 2011 of $9.5 million or $0.16 per share, based on average shares outstanding of 57.9 million. Net income for the fourth quarter of 2012 included total non-cash stock compensation expenses of $0.6 million compared to $1.2 million in the fourth quarter of 2011.

Cash, cash equivalents and short-term investments as of December 31, 2012 were $41.2 million, compared to $21.6 million as of September 30, 2012, and $52.2 million as of December 31, 2011.

Cash gain in the quarter was $19.5 million compared to a cash burn of $7.8 million in the third quarter of 2012. The current quarter cash position was positively impacted by the receipt of $30 million from the expanded licensing agreement with and stock purchase by Intuitive Surgical, and negatively impacted by a $620,000 valuation adjustment of a short-term investment. Excluding these two items, cash burn in the quarter would have been $9.9 million. The third quarter cash burn was positively impacted by a $1.5 million insurance reimbursement. Excluding this item, third quarter cash burn would have been approximately $9.3 million.

2012 Full Year Financial Results

Total revenue for the year ended December 31, 2012 was $17.6 million, compared to $22.1 million for 2011, a decrease of 20%. In 2012, the Company shipped 12 robotic catheter systems, recorded revenue on 13 systems, sold a record 2,807 catheters, and physicians performed a record 2,688 estimated procedures. These results compare to 2011 shipments of 13 robotic catheter systems, revenue on 23 systems, catheter sales of 2,787 and estimated procedures performed by physicians of 2,498. 2011 revenue was higher than 2012 primarily due to the inclusion of 12 systems in 2011 revenue which had been shipped in 2010 and prior, compared to only 5 systems in 2012 revenue which had been shipped in previous years.

Total operating expenses for 2012 were $42.1 million, compared to 2011 operating expenses of $43.5 million which included $10.6 million of funded research and development credits from the Philips agreement (which were recorded as a reduction of expense in 2011). Excluding these research and development credits, 2011 operating expenses were 22.0% higher than 2012 operating expenses primarily due to additional development costs associated with the Company's Magellan System and higher employee related costs.

The Company's net loss for 2012, including non-cash stock compensation expense of $2.9 million, and a gain on the licensing of intellectual property of $20.0 million, was $22.1 million, or $0.35 loss per basic and diluted share, based on average basic and diluted shares outstanding of 62.5 million. The Company's net loss in 2011, including non-cash stock compensation expense of $6.7 million, and a gain on the sale of intellectual property of $23.0 million, was $16.7 million, or $0.30 loss per basic and diluted share, based on average basic and diluted shares outstanding of 55.4 million.

Full Year 2013 Outlook

Hansen Medical will continue to focus on its three strategic initiatives of launching the Magellan Robotic system, driving EP procedure adoption, and achieving operational excellence. The company anticipates growth in total robotic system shipments in 2013 compared to 2012, as well as growth in procedures and catheter sales. However, given the uncertainty of the timing of system shipments, the company is not in a position to provide specific financial guidance.

We expect continued improvement in gross margins over 2012 levels based on our current volume assumptions of product sales and increased efficiency from our cost savings initiatives. We also expect that operating expenses will increase moderately as we anticipate adding resources to support the commercial launch of our Magellan System and the continuing adoption of our Sensei System. We will continue to invest in new products in 2013, and the company anticipates the commercial launch of our 6F vascular catheter for use in smaller vessel, peripheral applications by the end of 2013.

Finally, the Company's year-end cash position of $41.2 million is expected to be sufficient to fund the Company's operations for at least the next twelve months as we continue to execute on our strategy.

"Hansen Medical is shifting the focus of its resources towards sales and marketing in order to further support the global launch of our Magellan System. We will continue to leverage the positive data being generated by physicians with our technology in order to drive further adoption of intravascular robotics around the world," concluded Mr. Barclay.

Hansen Medical Conference Call

Company management will hold a conference call to discuss its 2012 full year and fourth quarter results today, February 27, 2013 at 5:00 p.m. ET (2:00 p.m. PT). Investors are invited to listen to the call live via the Internet using the link available within the "Investor Relations" section of Hansen Medical's website at www.hansenmedical.com. Additionally, participants can dial into the live conference call by calling 877-941-1427 or 480-629-9664 (international callers). An audio replay of the webcast will be available approximately one hour after the completion of the conference call through March 6, 2013, by calling 877-870-5176 or 858-384-5517 (international callers), and entering access code 4593337.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, is the global leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, NorthStar™ Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone both CE marking and 510(k) clearance and are commercially available in the European Union, and the U.S. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan Control Catheter are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S. the Company's Sensei X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the potential benefits of our Magellan Robotic System for hospitals, patients and physicians, expectations of shipments and installations of our robotic systems, catheter sales, and procedures, expectations of gross margins and operating expenses for 2013, the sufficiency of the company's cash resources for supporting the Company's operations, expected efficiencies from cost saving initiatives, and the anticipated timing of commercially launching a 6F vascular catheter. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; the commercial viability of our products in the vascular markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of economic conditions on capital spending by our potential customers; the uncertain timelines for the sales cycle for newly introduced products; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; our ability to manage expenses and cash flow, and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed with the SEC on November 9, 2012 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), Sensei and Lynx are registered trademarks, and Magellan and NorthStar are trademarks of Hansen Medical, Inc. in the United States and other countries.

                               HANSEN MEDICAL

              Condensed Consolidated Statements of Operations
                   (in thousands, except per share data)

                                  Three months ended        Year ended
                                     December 31,          December 31,
                                 --------------------  --------------------
                                    2012       2011       2012       2011
                                 ---------  ---------  ---------  ---------
Revenues                         $   4,344  $   6,170  $  17,636  $  22,129
Cost of revenues                     3,476      4,526     14,026     17,211
                                 ---------  ---------  ---------  ---------
Gross profit                           868      1,644      3,610      4,918
                                 ---------  ---------  ---------  ---------
Operating expenses:
  Research and development           3,494      1,898     16,126     12,156
  Selling, general and
   administrative                    6,801      8,612     25,987     31,428
                                 ---------  ---------  ---------  ---------
Total operating expenses            10,295     10,510     42,113     43,584
Gain on licensing of
 intellectual property              20,000         --     20,000         --
Gain on sale of intellectual
 property                               --         --         --     23,000
                                 ---------  ---------  ---------  ---------
Gain (loss) from operations         10,573     (8,866)   (18,503)   (15,666)
Other income (expense), net           (886)      (620)    (3,528)    (1,046)
                                 ---------  ---------  ---------  ---------
Net income (loss) before income
 taxes                               9,687     (9,486)   (22,031)   (16,712)
Income tax expense                     114         --        114         --
                                 ---------  ---------  ---------  ---------
Net income (loss)                $   9,573  $  (9,486) $ (22,145) $ (16,712)
                                 =========  =========  =========  =========
Basic net income (loss) per
 share                           $    0.15  $   (0.16) $   (0.35) $   (0.30)
                                 =========  =========  =========  =========
Diluted net income (loss) per
 share                           $    0.15  $   (0.16) $   (0.35) $   (0.30)
                                 =========  =========  =========  =========
Shares used to compute basic net
 income (loss) per share            65,336     57,881     62,472     55,362
                                 =========  =========  =========  =========
Shares used to compute diluted
 net income (loss) per share        65,890     57,881     62,472     55,362
                                 =========  =========  =========  =========

                               HANSEN MEDICAL

                    Condensed Consolidated Balance Sheets
                               (in thousands)

                                                  December 31,  December 31,
                                                      2012          2011
                                                 ------------- -------------

  Cash, cash equivalents and short-term
   investments                                   $      41,173 $      52,210
  Accounts receivable                                    5,235         5,493
  Inventories, net                                       9,134         6,617
  Deferred cost of revenues                                167         1,573
  Prepaids and other current assets                      1,765         1,829
  Property and equipment, net                            6,040         8,300
  Note receivable                                           --            --
  Other assets                                             578           737
                                                 ------------- -------------

Total assets                                     $      64,092 $      76,759
                                                 ============= =============

                    Liabilities and Stockholders' Equity

  Accounts payable                               $       3,056 $       2,944
  Deferred revenues                                      2,770         6,438
  Debt                                                  29,417        29,147
  Other liabilities                                      4,110         4,749
                                                 ------------- -------------

Total liabilities                                       39,353        43,278
                                                 ------------- -------------

Stockholders' equity                                    24,739        33,481
                                                 ------------- -------------

Total Liabilities and Stockholders' Equity       $      64,092 $      76,759
                                                 ============= =============

Investor Contacts:
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc.

FTI Consulting, Inc.
Brian Ritchie
Email Contact

John Capodanno
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
The Internet of Things (IoT) is going to require a new way of thinking and of developing software for speed, security and innovation. This requires IT leaders to balance business as usual while anticipating for the next market and technology trends. Cloud provides the right IT asset portfolio to help today’s IT leaders manage the old and prepare for the new. Today the cloud conversation is evolving from private and public to hybrid. This session will provide use cases and insights to reinforce the value of the network in helping organizations to maximize their company’s cloud experience.
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have spoken with, or attended presentations from, utilities in the United States, South America, Asia and Europe. This session will provide a look at the CREPE drivers for SmartGrids and the solution spaces used by SmartGrids today and planned for the near future. All organizations can learn from SmartGrid’s use of Predictive Maintenance, Demand Prediction, Cloud, Big Data and Customer-facing Dashboards...
IoT is still a vague buzzword for many people. In his session at Internet of @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, will discuss the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. The presentation will also discuss how IoT is perceived by investors and how venture capitalist access this space. Other topics to discuss are barriers to success, what is new, what is old, and what the future may hold.
Whether you're a startup or a 100 year old enterprise, the Internet of Things offers a variety of new capabilities for your business. IoT style solutions can help you get closer your customers, launch new product lines and take over an industry. Some companies are dipping their toes in, but many have already taken the plunge, all while dramatic new capabilities continue to emerge. In his session at Internet of @ThingsExpo, Reid Carlberg, Senior Director, Developer Evangelism at salesforce.com, to discuss real-world use cases, patterns and opportunities you can harness today.
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
Noted IoT expert and researcher Joseph di Paolantonio (pictured below) has joined the @ThingsExpo faculty. Joseph, who describes himself as an “Independent Thinker” from DataArchon, will speak on the topic of “Smart Grids & Managing Big Utilities.” Over his career, Joseph di Paolantonio has worked in the energy, renewables, aerospace, telecommunications, and information technology industries. His expertise is in data analysis, system engineering, Bayesian statistics, data warehouses, business intelligence, data mining, predictive methods, and very large databases (VLDB). Prior to DataArchon, he served as a VP and Principal Analyst with Constellation Group. He is a member of the Boulder (Colo.) Brain Trust, an organization with a mission “to benefit the Business Intelligence and data management industry by providing pro bono exchange of information between vendors and independent analysts on new trends and technologies and to provide vendors with constructive feedback on their of...
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how these devices generate enough data to learn our behaviors and simplify/improve our lives. What if we could connect everything to everything? I'm not only talking about connecting things to things but also systems, cloud services, and people. Add in a little machine learning and artificial intelligence and now we have something interesting...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) irreversibly encoded. In his session at Internet of @ThingsExpo, Peter Dunkley, Technical Director at Acision, will look at how this identity problem can be solved and discuss ways to use existing web identities for real-time communication.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn real-world benefits of WebRTC and explore future possibilities, as WebRTC and IoT intersect to improve customer service.
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder of TeleStax, an Open Source Cloud Communications company that helps the shift from legacy IN/SS7 telco networks to IP-based cloud comms. An early investor in multiple start-ups, he still finds time to code for his companies and contribute to open source projects.
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other machines.
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice services to the modern P2P RTC era of OTT cloud assisted services.
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehension and conference efficiency.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example to explain some of these concepts including when to use different storage models.
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridstore delivers vmOptimized™ Storage that self-optimizes to each application or VM across both virtual and physical environments. Leveraging a grid architecture, Gridstore delivers the first end-to-end storage QoS to ensure the most important App or VM performance is never compromised. The storage grid, that uses Gridstore’s performance optimized nodes or capacity optimized nodes, starts with as few a...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changing the data processing model for all information devices. In particular, in the area known as M2M (Machine-To-Machine), there are great expectations that information with a new type of value can be produced using a variety of devices and sensors saving/sharing data via the network and through large-scale cloud-type data processing. This consortium believes that attaching a huge number of devic...